<?xml version="1.0" encoding="UTF-8"?>

<document id="DDI-DrugBank.d706"> 
   <sentence id="DDI-DrugBank.d706.s0" text="Catecholamine-depleting drugs (e.g., reserpine) may have an additive effect when given with beta-blocking agents. " new_text="Catecholamine-depleting@@drugs@@(e.g.@@,@@reserpine@@)@@may@@have@@an@@additive@@effect@@when@@given@@with@@beta-blocking agents@@.@@"> 
      <entity id="DDI-DrugBank.d706.s0.e0" charOffset="37-45" type="drug" text="reserpine" position="4"/>  
      <entity id="DDI-DrugBank.d706.s0.e1" charOffset="92-111" type="group" text="beta-blocking agents" position="14"/>  
      <pair id="DDI-DrugBank.d706.s0.p0" e1="DDI-DrugBank.d706.s0.e0" e2="DDI-DrugBank.d706.s0.e1" ddi="true" type="effect" flags="True" e1_name="reserpine" e2_name="beta-blocking agents" e1_pos="4" e2_pos="14" path="4@@5@@7@@12@@14@@">reserpine@@@@amod@@)@@nsubj@@have@@advcl@@given@@prep_with@@beta-blocking agents</pair> 
   </sentence>  
   <sentence id="DDI-DrugBank.d706.s1" text="Patients treated with extended release metoprolol succinate plus a catecholamine depletor should therefore be closely observed for evidence of hypotension or marked bradycardia, which may produce vertigo, syncope, or postural hypotension." new_text="Patients@@treated@@with@@extended@@release@@metoprolol succinate@@plus@@a@@catecholamine@@depletor@@should@@therefore@@be@@closely@@observed@@for@@evidence@@of@@hypotension@@or@@marked@@bradycardia@@,@@which@@may@@produce@@vertigo@@,@@syncope@@,@@or@@postural@@hypotension@@.@@"> 
      <entity id="DDI-DrugBank.d706.s1.e0" charOffset="39-58" type="drug" text="metoprolol succinate" position="5"/> 
   </sentence> 
</document>
